Skip to content
Open access

Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis

Oct 2026 · JAMA Neurology · 0 citations · 44 references
Medicine

Abstract

This cohort study investigates if anti-CD20 treatment is associated with an increase in the risk of inflammatory bowel disease in individuals with multiple sclerosis (MS).

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.